OPA1 identified as regulator of mitochondrial dysfunction-driven liver fibrosis in MASLD

Researchers have posted a preprint to bioRxiv describing large-scale genomic analyses of mitochondrial genes — covering mitophagy, fusion, and fission — in cohorts of patients with metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). The work identifies OPA1, a dynamin-like GTPase that governs the fusion of inner mitochondrial membranes, as a central regulator of the fibrotic response in this condition.

Progressive hepatic fibrosis is recognised as the principal determinant of morbidity and mortality in MASLD/MASH. The preprint's authors propose that mitochondrial damage-associated molecular patterns (mito-DAMPs) released from injured hepatocytes act as a mechanistic bridge between organelle dysfunction and fibrosis-promoting signalling. OPA1's role in maintaining mitochondrial quality control and limiting mito-DAMP release is presented as a candidate node through which mitochondrial dynamics shape disease trajectory.

The work has not yet been peer-reviewed. If the findings are confirmed through independent validation and peer review, they may offer a mechanistic framework for understanding fibrosis risk in MASLD that could inform future research directions. The study draws on human genomic data, though specific cohort sizes and analytical methods should be assessed by reading the primary preprint.